MassMutual backs XUND

XUND , an Austrian healthtech company, has raised its seed funding to €8 million, up from €6 million in 2022. Thieme Group, a medical information provider, has joined as a new investor, along with existing backers MMC Ventures and MassMutual Ventures. This investment will support the development of Medical Large Language Models (MedLLMs) leveraging XUND’s expertise in Natural Language Processing (NLP) and Thieme’s medical content, aimed at delivering personalized medical information.

XUND, known for its software as a medical device (SaMD) that supports the entire patient lifecycle, has been partnering with Thieme Group since 2020 to enhance patient communication. This latest funding round will further their collaboration and propel digital health innovation, focusing on creating MedLLMs to offer dynamic, personalized medical content. The partnership, which showcases a prototype at Europe’s leading digital health event, DMEA, combines XUND’s AI and NLP technology with Thieme’s medical content.

“XUND is a market leader in developing AI tools for healthcare, and this new partnership provides access to a unique and valuable dataset to continue their development of Medical LLMs. We’re delighted to continue supporting XUND through the next stage of growth.” – Ryan Collins, Managing Partner at MassMutual Ventures.